Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Revenue (2016 - 2025)

Northwest Biotherapeutics' Revenue history spans 16 years, with the latest figure at $672000.0 for Q4 2025.

  • Quarterly results put Revenue at $672000.0 for Q4 2025, up 190.91% from a year ago — trailing twelve months through Dec 2025 was $1.4 million (changed 0.29% YoY), and the annual figure for FY2025 was $1.4 million, changed 0.29%.
  • Revenue for Q4 2025 was $672000.0 at Northwest Biotherapeutics, up from $200000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $880000.0 in Q1 2023 to a low of $131000.0 in Q2 2025.
  • The 5-year median for Revenue is $375000.0 (2025), against an average of $388421.1.
  • The sharpest move saw Revenue soared 20700.0% in 2021, then tumbled 74.31% in 2025.
  • Year by year, Revenue stood at $350000.0 in 2021, then skyrocketed by 70.57% to $597000.0 in 2022, then fell by 25.46% to $445000.0 in 2023, then crashed by 48.09% to $231000.0 in 2024, then soared by 190.91% to $672000.0 in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $672000.0, $200000.0, and $131000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.